



(51) International Patent Classification:

A61P 35/00 (2006.01) C07D 519/00 (2006.01)
C07D 487/04 (2006.01)

(21) International Application Number:

PCT/EP2020/072377

(22) International Filing Date:

10 August 2020 (10.08.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

19191299.7 12 August 2019 (12.08.2019) EP
20167707.7 02 April 2020 (02.04.2020) EP

(71) Applicants: **BAYER AKTIENGESELLSCHAFT** [DE/DE]; Kaiser-Wilhelm-Allee 1, 51373 Leverkusen (DE). **BAYER PHARMA AKTIENGESELLSCHAFT** [DE/DE]; Müllerstr. 178, 13353 Berlin (DE). **DEUTSCHES KREBSFORSCHUNGSZENTRUM** [DE/DE]; Im Neuenheimer Feld 280, 69120 Heidelberg (DE).

(72) Inventors: **LEFRANC, Julien**; Kurfürstenstr. 46b, 13467 Berlin (DE). **SCHMEES, Norbert**; Bondickstrasse 61, 13469 Berlin (DE). **ZORN, Ludwig**; Osianderweg 45A, 13509 Berlin (DE). **MEIER, Robin, Michael**; Gutenzeller Str. 52, 88489 Wain (DE). **HERBERT, Simon, Anthony**; Pufendorfstr. 7, 10249 Berlin (DE). **GÜNTHER, Judith**; Parkstr. 60, 13187 Berlin (DE). **GUTCHER, Ilona**; Paul-Robeson-Strasse 28, 10439 Berlin (DE). **RÖSE, Lars**; Fuchsring 82, 13465 Berlin (DE). **BADER, Benjamin**; Hillmannstr. 14, 13467 Berlin (DE). **STÖCKIGT, Detlef**; Siefertstr. 2, 14467 Potsdam (DE). **GORJÁNÁČZ, Mátyás**; Gurnemanzpfad 67, 13465 Berlin (DE). **KOBER, Christina**; Am Alten Bahnhof 8, 35457 Lollar (DE). **BUCHMANN, Bernd**; Erdmannstr. 44, 16540 Hohen Neuendorf (DE). **BÖHME, Stephan**; August-Euler-Zeile 10, 14089 Berlin (DE). **BOTHE, Ulrich**; Kavalierstraße 15, 13187 Berlin (DE). **PLATTEN, Michael**; Cambridgestr. 7, 69115 Heidelberg (DE). **BAUMANN, Daniel**; Friedensstr. 8a, 69121 Heidelberg (DE).

(74) Agent: **BIP PATENTS**; Alfred-Nobel-Str. 10, 40789 Monheim am Rhein NRW (DE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

Published:

— with international search report (Art. 21(3))

(54) Title: [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES



(I)

(57) Abstract: The present invention covers [1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds of general formula (I) in which R^1 , R^2 , R^3 , R^4 , R^5 , R^6 , R^7 and R^8 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of cancer or conditions with dysregulated immune responses or other disorders associated with aberrant AHR signaling, as a sole agent or in combination with other active ingredients.